Celldex Therapeutics (CLDX) Short term Debt (2010 - 2013)

Celldex Therapeutics' Short term Debt history runs 4 years deep, the most recent figure standing at $5.6 million for Q1 2013.

• On a quarterly basis, Short term Debt rose 6.35% year-over-year to $5.6 million in Q1 2013; TTM through Mar 2013 was $5.6 million, a 6.35% increase from a year earlier, with the FY2012 full-year figure at $5.6 million, down 8.87% from the prior year.
• Short term Debt improved to $5.6 million in Q1 2013 per CLDX's latest filing, from $5.6 million in the prior quarter.
• Across five years, Short term Debt topped out at $6.1 million in Q4 2011 and bottomed at $1.1 million in Q4 2010.
• The 4-year median for Short term Debt is $5.3 million (2012), against an average of $4.8 million.
• Across the five-year window, Short term Debt jumped 452.3% in 2011 and fell 8.87% in 2012, its largest moves.
• Year by year, Short term Debt stood at $1.1 million in 2010, then soared by 452.3% to $6.1 million in 2011, then decreased by 8.87% to $5.6 million in 2012, then grew by 0.68% to $5.6 million in 2013.
• Per Business Quant, the three latest CLDX Short term Debt figures stand at $5.6 million (Q1 2013), $5.6 million (Q4 2012), and $5.3 million (Q3 2012).